A review. New antiemetics of different classes are still needed to help manage PONV effectively, especially the treatment of established PONV after the failure of common prophylactic antiemetics such as 5-HT3-antagonists and corticosteroids. I.v. amisulpride, a drug with a long history of safe use in oral form as an antipsychotic, has recently been approved in the US (trade name: Barhemsys) as an i.v. antiemetic for the prevention and treatment of PONV. This review article summarizes the published data on the clin. pharmacol., safety, and efficacy of i.v. amisulpride as an antiemetic, supplemented by published data on oral amisulpride, where relevant to the i.v. form. Literature was obtained via the PubMed search terms 'i.v. amisulpride' and 'amisulpride AND safety'. Both primary and secondary pharmacol. are covered, along with clin. pharmacokinetics (distribution, metabolism, and excretion). The review of clin. safety and efficacy includes data from four studies in the prevention of PONV, two in the treatment of PONV and two investigating effects on the QT interval of the ECG in healthy volunteers.: Given the importance of sufficient PONV prevention for patients and the healthcare system, the availability of i.v. amisulpride is helpful, restoring the dopamine-antagonist class as a potential mainstay in both combination prophylaxis and treatment.